Advertisement
Advertisement
-
TOPIC
 / company

Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals: A leading Chinese pharmaceutical company, headquartered in Lianyungang, Jiangsu, with corporate offices in Shanghai and a global presence including R&D centres in the US and Europe. It specialises in the research, development, manufacturing, and distribution of innovative drugs, primarily focusing on oncology, surgical medicines, cardiovascular, and metabolic diseases. The company is recognised as China’s largest listed pharmaceutical firm and consistently ranks among the top global pharmaceutical companies. Its overall business focus is on innovation, significant R&D investment, and global expansion to address unmet medical needs.
Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Advertisement
Advertisement
Advertisement
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
China stock market

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

Consumer retailers, carmakers and internet companies are expected to bear the brunt of fund outflows.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Chinese pharmaceutical companies’ licensing deals made up about 50 per cent of the total value of such transactions worldwide in the first eight months of the year. Photo: Shutterstock
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Employees work on the production line of Shijiazhuang No 4 Pharmaceutical in Shijiazhuang, Hebei province. Photo: VCG/VCG via Getty Images
Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Advertisement
Advertisement
Advertisement
IPO

Zijin Gold’s Hong Kong IPO draws GIC, Millennium and Hillhouse, sources say

The company could raise more than US$3 billion and could start taking orders from other investors and the public as soon as Friday.

Zijin Gold, a unit of China’s biggest miner, Zijin Mining Group, has been pursuing rapid expansions and numerous acquisitions across gold and copper. Photo: Reuters
Banking & finance

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

IPO

Hong Kong IPO pipeline swells as Chinese tech listings lure global investors

More than 200 companies await approval amid ‘strong global interest in China’s tech sector’, CEO of bourse operator says.

Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

The headquarters of Jiangsu Hengrui Pharmaceutical in Lianyungang Economic and Technological Development Zone, in Jiangsu province. Photo: Costfoto/Future Publishing via Getty Images
China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

videocam
China goes big on weight-loss drugs in Novo, Eli Lilly challenge
Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Biomedicine: Companies

Opinion | Biotech successes helping Chinese intellectual property go global

After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own innovations.

videocam
Wealth management

Shareholders of Chinese firms eye Hong Kong for family offices: asset manager

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family offices.

Wang Fengyu, founder and chairman of Hong Kong-based Oakwise Capital. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement